Answer
It is unknown whether lumasiran sodium (Oxlumo) or its metabolites pass into human breast milk, and a risk to newborns or infants cannot be excluded.
Sources for this answer
- Oxlumo 94.5 mg/0.5 mL solution for injectionAlnylam UK Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 8Document updated
Sources checked